eligibility_summary
Adults ≥18 with CD20+ B‑NHL. Phase Ib: R/R indolent (≥1L) or aggressive (≥2L) incl DLBCL/FL/MCL/MZL. Phase IIa: FL, MZL, DLBCL after anti‑CD20 1L (2L). Need measurable disease, ECOG 0–2, ≥3‑mo survival, washouts, resolved AEs, adequate organs, contraception. Exclude CNS involvement, transplant/live vaccine, other active cancer, autoimmune disease, major surgery/VTE, steroids/antiplatelets, ILD/TB, uncontrolled illness/cardiac, HIV/HBV/HCV, serious infection, mAb allergy, pregnancy, stroke/GI bleed ≤6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase Ib/IIa, single-arm combo in relapsed/refractory CD20+ B‑cell NHL (DLBCL, FL, MZL, MCL). Interventions and mechanisms: • IMM0306: antibody fusion protein (IgG1 Fc, ADCC‑enhanced) combining an anti‑CD20 mAb with the CD47‑binding domain of SIRPα. Mechanisms: binds CD20 on malignant B cells for opsonization, blocks CD47–SIRPα “don’t‑eat‑me” checkpoint to enable macrophage phagocytosis (ADCP), engages Fcγ receptors to drive NK‑cell/macrophage ADCC. • Lenalidomide (Revlimid): small‑molecule IMiD, binds cereblon (CRBN) to degrade Ikaros/Aiolos, enhancing T‑cell/NK‑cell cytotoxicity, modulating cytokines, exerting anti‑angiogenic and direct antiproliferative effects. Cells/pathways targeted: CD20+ B cells, CD47–SIRPα innate immune checkpoint, FcγR‑mediated ADCC, macrophages, NK cells, T cells, CRBN E3 ligase pathway, angiogenesis signaling.